In a Law360 article, life science and intellectual property transactions partner David McIntosh, health care partner Margaux Hall, who leads the firm’s drug pricing and price reporting group, and life science transactions associates Kyle Connors and Zoe Dettelbach authored an article analyzing the evolving landscape for the life sciences industry following the implementation of the Inflation Reduction Act’s drug price negotiation program.
The article notes that the “IRA is broadly affecting regulatory and corporate strategy for biotechnology and pharmaceutical firms of all sizes” and highlights that the actual economic impact on manufacturers “cannot be accurately estimated by comparing the percentage discount from list price.”
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.